- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
- Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
- Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
- Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
- Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
More ▼
Key statistics
On Monday, Century Therapeutics Inc (IPSC:NSQ) closed at 3.05, 138.28% above the 52 week low of 1.28 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.10 |
---|---|
High | 3.37 |
Low | 2.98 |
Bid | -- |
Offer | -- |
Previous close | 3.05 |
Average volume | 140.44k |
---|---|
Shares outstanding | 80.69m |
Free float | 72.96m |
P/E (TTM) | -- |
Market cap | 246.11m USD |
EPS (TTM) | -2.30 USD |
Data delayed at least 15 minutes, as of Apr 22 2024 21:00 BST.
More ▼